Loading...
Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis
- Ticker
- RGNX
- Price
- 15.98
- Stock movement up
- +0.10 (0.78%)
- Company name
- Regenxbio Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 657.09M
- Ent value
- 962.04M
- Price/Sales
- 7.79
- Price/Book
- -
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return (CAGR)
- 29.80%
- 3 year return (CAGR)
- -
- 5 year return (CAGR)
- -
- 10 year return (CAGR)
- -
Last updated: 2025-12-04
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
RGNX does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 7.79 |
| Price to Book | - |
| EV to Sales | 11.41 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 50.62M |
| EPS (TTM) | -3.44 |
| FCF per share (TTM) | -2.06 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 161.32M |
| Gross profit (TTM) | 80.62M |
| Operating income (TTM) | -154.93M |
| Net income (TTM) | -177.91M |
| EPS (TTM) | -3.44 |
| EPS (1y forward) | -2.06 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 49.98% |
| Operating margin (TTM) | -96.04% |
| Profit margin (TTM) | -110.29% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 58.80M |
| Net receivables | 26.47M |
| Total current assets | 331.97M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 239.87M |
| Total assets | 525.20M |
| Accounts payable | 22.27M |
| Short/Current long term debt | 268.14M |
| Total current liabilities | 124.57M |
| Total liabilities | 363.75M |
| Shareholder's equity | 161.45M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -103.30M |
| Capital expenditures (TTM) | 2.98M |
| Free cash flow (TTM) | -106.28M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -110.20% |
| Return on Assets | -33.88% |
| Return on Invested Capital | -83.83% |
| Cash Return on Invested Capital | -50.08% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 12.88 |
| Daily high | 13.77 |
| Daily low | 12.82 |
| Daily Volume | 941K |
| All-time high | 82.15 |
| 1y analyst estimate | 30.36 |
| Beta | 1.14 |
| EPS (TTM) | -3.44 |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | 3 Mar 2026 |
Downside potential
Loading...
Downside potential data
| RGNX | S&P500 | |
| Current price drop from All-time high | -80.55% | -0.89% |
| Highest price drop | -93.54% | -19.00% |
| Date of highest drop | 8 Apr 2025 | 8 Apr 2025 |
| Avg drop from high | -88.99% | -2.49% |
| Avg time to new high | - | 6 days |
| Max time to new high | 290 days | 89 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
657.09M
Marketcap category
Small-cap
Description
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase III clinical trial for the treatment of Duchenne muscular dystrophy, as well as RGX-121 for the treatment of mucopolysaccharidosis type II. It also develops RGX-111 for the treatment of mucopolysaccharidosis type I, RGX-181 for the treatment of late-infantile neuronal ceroid lipofuscinosis type 2, and RGX-381 for the treatment of the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.
Employees
353
Website
Investor relations
-
SEC filings
CEO
Kenneth T. Mills
Country
USA
City
Rockville
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page